
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Harry M. Meade, PhD, is senior vice president of research and development at GTC Biotherapeutics, Inc.
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Published: August 1st 2006 | Updated: